Carsten Brunn, PhD

Articles by Carsten Brunn, PhD

Re-Dosing With Gene Therapies in Rare Diseases

ByTakashi Kei Kishimoto, PhD,Carsten Brunn, PhD

June 15th 2022

Takashi Kei Kishimoto, PhD, and Carsten Brunn, PhD, the chief science and executive officers of Selecta Biosciences, discussed the immunogenicity-mitigating properties of ImmTOR.

Carsten Brunn, PhD

Articles by Carsten Brunn, PhD

Re-Dosing With Gene Therapies in Rare Diseases

Latest Updated Articles

Trending on CGTlive®

Sarepta Therapeutics’ Limb-Girdle Muscular Dystrophy Gene Therapy SRP-9003 Produces “Robust Expression” of β-SG in Phase 3 Trial

AAVantgarde’s Stargardt Gene Therapy AAVB-039 Garners FDA Orphan Drug Designation, Cleared for Trial in UK